SCHEMBL3764867

SCHEMBL3764867

CCC(CC(N)C1=CC(C(C)C)C(=O)O1)CC(C)c1ccc2[nH]cc(CCCOC)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 10/20 0.36
HTR1B P28222 10/20 0.33
HTR1A P08908 9/20 0.33
MAPT P10636 3/20 0.33
MAPK1 P28482 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
HTR2A P28223 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HTR2C P28335 1/20 0.31
HTR2B P41595 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770011 0.86 HTR1D (0.36) HTR1DHTR1BHTR1AMAPTMAPK1
SCHEMBL3767896 0.80 HTR1D (0.32) HTR1D
SCHEMBL3764865 0.79 HTR1D (0.35) HTR1DHTR1BHTR1AHTR2AHTR2C
SCHEMBL78477 0.69 HTR1D (0.66) HTR1DHTR1BHTR1AMAPTHTR2A
SCHEMBL28942828 0.69 HTR1D (0.35) HTR1DHTR1BHTR1AMAPTMAPK1
SCHEMBL4757239 0.67 TSHR (0.31)
SCHEMBL3465853 0.67 TSHR (0.31)
SCHEMBL4756462 0.67 TSHR (0.31)
SCHEMBL3770009 0.67 HTR1D (0.36) HTR1DHTR1BHTR1AMAPTHTR2A
SCHEMBL9200459 0.64 HTR1D (0.49) HTR1DHTR1BHTR1AMAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851634-B2 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension NOVARTIS AG (CH) 2010-12-14 US disclosed
US-20080280895-A1 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension NOVARTIS AG (CH) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280895-A1 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension REN, AGTR1, AGTR2 HTR1D 197/4885HTR1B 213/4885HTR1A 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.